Drugdocs | Trikafta

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Trikafta

Chemical Name	elexacaftor, ivacaftor, and tezacaftor
Dosage Form	Tablet (oral; 100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor, co-packaged with 150 mg ivacaftor)
Drug Class	CFTR potentiators
System	Respiratory
Company	Vertex Pharms Inc
Approval Year	2019

Indication

Trikafta is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.

Last updated on 11/10/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Trikafta (elexacaftor, ivacaftor, and tezacaftor) Prescribing Information	2020	Vertex Pharmaceuticals

Document Title	Year	Source
Modulator treatments for cystic fibrosis: effectiveness and value.	2020	ICER

Document Title	Year	Source
Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review.	2020	Journal of The Academy of Nutrition and Dietetics
From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis.	2020	International Journal of Molecular Sciences